

Hamburg, Germany  
May 15th, 2020

## AmpTec signs agreement for process development of large scale therapeutic mRNA purification

**AmpTec, manufacturer of customized therapeutic mRNA products, today announced it has signed an agreement focused on process development of a novel large scale mRNA purification technology using Thermo Fisher Scientific's POROS Oligo (dT) Affinity Resins. Therapeutic mRNAs are becoming increasingly important as a promising option for rapid development of vaccines against infectious disease such as COVID-19.**

In light of the pandemic and widespread infections, large quantities of mRNA-based therapies are in high demand. In order to meet these needs globally, AmpTec is intensively examining possible options for large-scale mRNA purification. Reverse phase HPLC is the current standard procedure, but scalability of the method is limited. Additionally, reverse phase uses flammable and toxic organic solvents, which are not preferred.

Thermo Fisher's POROS platform offers a rapid and highly scalable mRNA purification technology. The POROS Oligo (dT)25 resin helps enable simple

purification using salt and water, does not require hazardous reagents, and allows for purification of very large mRNA batches (into the kilogram range). POROS bulk chromatography resins are used throughout the industry, offering high-performance, high-throughput process-scale bioseparations.

Comparative trial mRNA purifications led by AmpTec using POROS Oligo (dT)25 resin demonstrated highly reproducible results with greater than 95 percent recovery using different mRNA sequences and lengths.

## PRESS RELEASE

Dr. Peter Scheinert, CEO at AmpTec says:

“We are very pleased with our relationship with Thermo Fisher and about this exciting opportunity to participate in the development of this new resin for mRNA purification. This promising technology will allow us to meet the increasing demands of mRNAs from our customers.”

### **About AmpTec**

AmpTec GmbH is a Hamburg (Germany) based internationally active contract manufacturing company (CMO) with comprehensive services for cGMP manufacturing of synthetic nucleic acids for biotech and pharma companies. The company was founded in May 2005 by Dr. Guido Krupp and Dr. Peter Scheinert and has a proven track-record of almost 15 years.

AmpTec has a highly motivated team of more than 40 employees with outstanding experience in GMP-compliant manufacturing of synthetic nucleic acids. Key products are synthetic fully functional mRNAs as drug substance or active pharmaceutical ingredient (API) for the pharmaceutical industry using mRNAs to develop a new category of medicines. All AmpTec products are produced in a highly regulated state-of-the-art GMP environment according to international cGMP guidelines.

### **Contact details**

AmpTec GmbH  
Amplification Technologies  
Königstr. 4A  
D-22767 Hamburg  
Germany

Dr. Guido Krupp  
Dr. Peter Scheinert

Email: [info@amp-tec.com](mailto:info@amp-tec.com)  
Phone: +49 40 636 747 22  
Web: [www.amp-tec.com](http://www.amp-tec.com)